On March 18, 2020 THERADIAG (ISIN: FR0004197747, Mnémonique: ALTER), a company specializing in in vitro diagnostics and theranostics reported its annual results for the year ended December 31, 2019 and adopted by the Board of Directors on March 17, 2020 (Press release, Theradiag, MAR 18, 2020, View Source [SID1234555673]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2019 annual results
Notes: (1) Social accounts for 2018 of the company Theradiag restated for consolidation items, the Prestizia subsidiary not being consolidated since 2019. (2) Following a final post-publication audit of turnover of Jan. 30, 2020, turnover has been adjusted to € 9,638 thousand instead of € 9,647 thousand previously
Bertrand de Castelnau, CEO of Theradiag , comments "Theradiag’s 2019 annual results are fully in line with our expectations. Excluding exceptional items, the result for the year is even closer to breakeven, it is a first great achievement on the path to profitability. Innovation remains absolutely central to Theradiag’s growth and we are very satisfied with our continuous investment in R&D, in theranostics in particular with our new i-Track 10 automated system. We have before us important stages of development to come in 2020, particularly internationally in the United States, where we wish to accelerate our presence. We are pleased to announce today a tangible improvement in our financial indicators and look forward to the next few years. "
"The priorities for 2019 were clear and the team’s commitment to achieving them was productive. The exceptional result generated allows Theradiag to pursue its development strategy in a calm manner. The company has real growth potential to assert itself even more in 2020, in France and on its priority markets, as the leader in monitoring biotherapies, " added Pierre Morgon, Chairman of the Board of Directors.
[…]
Financial calendar:
Annual General Meeting, May 14, 2020
Sales for the first half of 2020 , Tuesday July 21, 2020
Upcoming conferences in which Theradiag participates, subject to confirmation:
May 2-5, 2020: Digestive Disease Week (DDW) Congress, Chicago, USA
May 20-24, 2020: 11th International Autoimmunity Congress, Athens, Greece
June 25 to 26, 2020: Nils-Olivier Olsson conference at GEAI, Paris
June 25 to 26, 2020: Francophone Days of Hepato-gastroenterology and Digestive Oncology 2020 (JFHOD), Paris.